Patent intelligence · US
US 9523691
Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
Patent details — US 9523691
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 20, 2016
- Expiration
- Dec 15, 2036
- Applicant
- INSTITUT DE CANCEROLOGIE DE L'OUEST
- Claims
- 11
- CPC classes
- A61K, A61K31/4745, A61K31/513, A61K31/519
Quick answer
US 9523691 (Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis) is held by INSTITUT DE CANCEROLOGIE DE L'OUEST. Status: granted. Granted Dec 20, 2016. Expires Dec 15, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INSTITUT DE CANCEROLOGIE DE L'OUEST
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/4745, A61K31/513, A61K31/519, A61K31/555, A61K33/243
More from INSTITUT DE CANCEROLOGIE DE L'OUEST
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted
Related coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy
The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) for the adjuvant treatment of adult patients with muscle-invasive bladder cancer (MIBC) who have ctDNA molecular residual disease (MRD) positivity after radical cystectomy. This approval signifies a major step forward in personalized adjuvant therapy for this patient population.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
Frequently asked questions
What is US patent 9523691?
US 9523691 (Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis) is held by INSTITUT DE CANCEROLOGIE DE L'OUEST. Status: granted. Granted Dec 20, 2016. Expires Dec 15, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9523691?
INSTITUT DE CANCEROLOGIE DE L'OUEST is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 9523691 expire?
Our index shows an expiration date of Dec 15, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.